{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016473","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2023-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.307510+00:00","generated_at":"2026-06-09T22:43:11.485202+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Olema appoints Scott Garland to Board; brings commercial expertise for late-stage palazestrant development","bullets":["Scott Garland appointed to Board as Class III director effective Oct 16, 2023; term through 2026 annual meeting.","Received initial equity: options for 21,520 shares (3-year vest) and 14,347 shares (vests by 2024 annual meeting).","Annual cash retainer $40,000 plus $6,000 for Compensation Committee service; standard indemnification agreement.","Garland formerly CEO of Portola (led Andexxa launch and Alexion acquisition) and held senior roles at Exelixis, Genentech, Amgen.","Company highlights his commercial leadership as palazestrant advances to Phase 3 for breast cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016473","json":"https://secwatch.observer/filing/0001558370-23-016473.json","markdown":"https://secwatch.observer/filing/0001558370-23-016473.md","text":"https://secwatch.observer/filing/0001558370-23-016473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023016473/0001558370-23-016473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023016473/olma-20231013x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:43:11.485202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}